Photographer: Anne-Li Engström
Pipeline meetings with pharmaceutical companies are an important source of information for Amgros, via Horizon Scanning, to forecast the medicines we can expect to be marketed on the Danish market in the future.
The companies describe what they expect to launch in the years to come. This applies for new medicines and new indications for existing medicines.
- Pharmaceutical substance and trade (brand) name
- Planned indication
- Medicinal value compared with existing treatment
- Timetable for application, authorisation and launch
- Population of patients who may be relevant users of the medicine in Denmark
- Possible budget impacts
- Information about upcoming patent expiries
- Expected price
Amgros takes part in pipeline meetings with representatives from Horizon Scanning and other relevant departments. This means that medicines suppliers have an opportunity to meet our specialists and ask questions.
Note, however, that Amgros is subject to the Access to Public Administration Files Act.
Read more
Horizon Scanning
Through Horizon Scanning, Amgros provides an overview of medicines and extensions of indication that are expected to be marketed in Denmark within the next two to three years.
READ MOREHorizon Scanning overviews
Horizon Scanning prepares lists of new medicines, extensions of indication and other extensions undergoing evaluation by the EMA.
READ MORE
Find your way through EMA
We monitor and register applications from pharmaceutical companies to the European Medicines Agency (EMA).
READ MORELatest news
If you would like to receive news from Amgros directly in your inbox, sign up for our newsletter. You can choose between general news or the latest news from Horizon Scanning.
SIGN UPContact
Moon Raagaard
Coordinator
I work on a broad range of coordination tasks for the team and with our stakeholders. For example, I'm responsible for coordinating negotiation meetings at Amgros when medicines are assessed by the Danish Medicines Council.